Ranking Profile - Actinium Pharmaceuticals Inc


Actinium Pharmaceuticals Inc (Actinium) develops antibody radiation conjugates (ARC), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company's pipeline products include Iomab-B for hematopoietic stem cell transplantation, Iomab-ACT for the treatment of GeneTx and Cell therapy conditioning, Actimab-A(CD33) for the treatment of relapsed/refractory AML. The three variants of Actimab-A developed by company are- Actimab-A (CD33) and CLAG-M; Actimab-A (CD33) and Venetoclax and Actimab-A (CD33) and Venetoclax with HMA. The company also offers AWE Technology Platform. It develops products to treat colon, prostrate and brain cancer. ATNM is headquartered in New York City, New York, the US.

Company info

Country (HQ): United States
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 222
Revenue (US$ m): 1 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

Actinium Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers